Following the announcement of the completion of its pre-Series C round of financing in July 2020, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO Technology” or the “Company”) officially announced the completion of over RMB 300 million in Series C financing. This round of financing was led by Loyal Valley Capital. Morningside Group, Shanghai Lingang Economic Development, Sherpa Healthcare Partners, Kunlun Investment, GP Hi-tech Capital, and BioTrack Capital participated as followers in the round.

CEC Capital Group has served as the Company’s financial advisor in OBiO Technology’s pre-Series C and Series C rounds of financing, and has helped the Company complete more than RMB 600 million in equity financing within the past six months.

About OBiO Technology (Shanghai) Corp., Ltd.

OBiO Technology (Shanghai) Corp., Ltd. was established in 2013 in Shanghai, China. It is a leading company in China integrating life science research services, gene therapy drug incubation, and clinical-grade recombinant virus preparation.

OBiO Technology’s core business consists of gene therapy recombinant virus research, development and production. The Company focuses on providing high-quality products and technical services in the field of biomedicine, and strives to become a benchmark for the domestic precision medicine industry.

About CEC Capital Group

Founded in 2000, CEC Capital Group is one of China’s leading investment banks focusing on the three major industries of healthcare, consumer, and TMT. The company is headquartered in Beijing, with offices in Shanghai. Its US affiliate, China eCapital Partners, LLC, has offices in Los Angeles and San Francisco.

In the three years from 2017 to 2019, CEC Capital Group has participated in financing and M&A transactions valued at a total of more than RMB 100 billion. In addition to its investment banking business, CEC Capital Group has been managing an RMB fund and a USD fund since 2014.

CEC Capital Group has the healthcare industry’s largest dedicated investment banking coverage team in China, with comprehensive coverage of the entire ecosystem and a market-leading position in the industry. The firm has advised on the largest number of healthcare-related private capital financing transactions over the past three years among China-based investment banks.